Fox Chase’s Dr. Jessica Karen Wong to Discuss Management of Metastatic Prostate Cancer at ESMO Education Conference

PHILADELPHIA (October 21, 2022)—Jessica Karen Wong, MD, MEng, of Fox Chase Cancer Center will discuss new trends in the management of oligometastatic prostate cancer, including the increased use of localized treatments such as radiation that are increasing local control and improving outcomes.

Wong’s presentation this weekend will be part of the European Society for Medical Oncology (ESMO) PA Conference. The free conference is designed to equip healthcare providers with the latest strategies to improve clinical practice and treatment outcomes in cancer care.

“Oligometastatic prostate cancer is an in-between state where the cancer has spread from the original site in the prostate to a few other locations,” said Wong, who is an assistant professor in the Department of Radiation Oncology at Fox Chase.

“Previously, when prostate cancer had spread beyond the prostate, curative therapy was no longer used and hormone therapy was your only option. Now patients in an oligometastatic state can benefit both from standard metastatic treatment and treatments that were previously reserved for localized prostate cancer patients alone,” added Wong, who is also assistant director of the Fox Chase Radiation Oncology Residency and Fellowship Training Program.

As newer diagnostic tests such as Prostate Specific Membrane Antigen PET scan become more widely used, Wong said, more patients will likely be classified as having oligometastatic disease. These diagnostic tests are much more sensitive and can find small areas of prostate cancer that would not have been detected using more traditional imaging.

“Oligometastatic patients are living longer and with less side effects due to modern treatment. Newer systemic therapy agents like enzalutamide, apalutamide, and abiraterone work on the androgen receptor pathway and can increase the efficacy of traditional androgen deprivation therapy,” Wong said.

Additionally, localized treatments like radiation to the prostate and stereotactic body radiation therapy to oligometastatic sites are also increasing local control, improving outcomes, and potentially reducing the need for systemic therapy, she added.

“As patients are living longer with oligometastatic disease, a number of new treatments are available for them, but the optimal combination of treatments is still unknown. A future goal is to find ways for these treatment to work together to have the best outcomes for patients.”


Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427